NCT04929379View on ClinicalTrials.gov

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetic Nephropathies
Interventions
DRUG

Fenofibrate

145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.

OTHER

Placebo

Inactive tablets identical to fenofibrate

Trial Locations (4)

13210

SUNY Upstate Medical University, Syracuse

48105

Brehm Center for Diabetes Research / University of Michigan, Ann Arbor

02215

Joslin Diabetes Center, Boston

01805

Lahey Hospital and Medical center, Burlington

All Listed Sponsors
collaborator

University of Michigan

OTHER

collaborator

University of Minnesota

OTHER

lead

Alessandro Doria

OTHER